Antithrombotic effect of FK506 vs cyclosporine in cardiac transplant recipients: potential implications in transplant arteriopathy

Journal of Heart and Lung Transplantation

Volumn 18, Issue 12, 1999, Pages 1228-1231

  Freudenberger, Ronald ^a   Alexis, Jeffrey ^b   Gass, Alan ^b   Fuster, Valentin ^b   Badimon, Juan ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; TACROLIMUS;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBRIN DEPOSITION; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; MALE; NONHUMAN; PRIORITY JOURNAL; THROMBOGENESIS; THROMBOGENICITY;

BLOOD COAGULATION; CYCLOSPORINE; FEMALE; HEART TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; TACROLIMUS; THROMBOSIS;

EID: 0032759578     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-2498(99)00094-7     Document Type: Article

References (10)

1. Salomon R., Hughes C., Schoen F., Payne D., Pober J., Libby P. Human coronary transplantation-associated atherosclerosis evidence for a chronic immune reaction to activated endothelial cells . Am J Pathol. 138:1991;791-798.
2. Faulk P., Labarrere C., Nelson D., Pitts D. Hemostasis fibrinolysis and natural anticoagulation in transplant vascular sclerosis. J Heart Lung Transplant. 14:1995;S158-S164.
3. Badimon L., Badimon J.J., Galvez A., Chesebro J., Fuster V. Influence of arterial damage and wall shear rate on platelet deposition ex vivo study in a swine model . Arteriosclerosis. 6:1986;312-320.
4. Dangas G., Badimon J., Coller B., et al. Administration of abciximab during percutaneous intervention reduces both ex vivo platelet thrombus formation and fibrin deposition. Implications for a potential anticoagulant effect of abciximab. Arterioscler Thromb Vasc Biol. 18:1998;1342-1349.
5. Naik U., Markell M., Ehrlich Y., Kornecki E. Cyclosporine A enhances agonist induced aggregation of human platelets by stimulating protein phosphorylation. Cell Mol Biol Res. 39:1993;257-264.
6. Muraki T, Sasaki Y, Gidding J, Ishii H, Kaneko T, Yamamoto J. Antithrombotic effect of FK506 versus prothrombotic effect of cyclosporine en vivo. Transplantation 60:308-31.
7. Clawsson K., Mayer A., Squifflet J., et al. Lipoprotein patterns in renal transplant patients a comparison between FK 506 and cyclosporine A patients . Transplant Proc. 30:1998;1292-1294.
8. Valantine H., Scroeder J. HMG-Co-A reductase inhibitors reduce transplant coronary artery disease and mortality. Evidence for antigen independent mechanisms? Circulation. 96:1997;1370-1373.
9. Fuster V., Fass D., Kaye M., Josa M., Zinmeister A., Bowie E. Arteriosclerosis in normal and von Willebrand pigs long-term prospective study and aortic transplantation study . Cir Res. 51:1982;587-593.
10. Fuster V., Lie J., Badimon L., Rosemark J., Bowie E. Spontaneous and diet induced coronary atherosclerosis in normal swine and swine with von Willebrand disease. Arteriosclerosis. 5:1985;67-73.